U.S. Markets close in 4 hrs 39 mins
  • S&P 500

    4,480.62
    +9.25 (+0.21%)
     
  • Dow 30

    35,294.59
    -0.17 (-0.00%)
     
  • Nasdaq

    14,942.87
    +45.53 (+0.31%)
     
  • Russell 2000

    2,265.53
    -0.12 (-0.01%)
     
  • Gold

    1,768.90
    +0.60 (+0.03%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.5930
    +0.0740 (+4.87%)
     
  • Vix

    16.77
    +0.47 (+2.88%)
     
  • GBP/USD

    1.3716
    +0.0039 (+0.2825%)
     
  • USD/JPY

    114.2790
    +0.6020 (+0.5296%)
     
  • BTC-USD

    61,908.36
    +1,080.35 (+1.78%)
     
  • CMC Crypto 200

    1,442.73
    -8.91 (-0.61%)
     
  • FTSE 100

    7,201.72
    -32.31 (-0.45%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Bantam Pharmaceutical Completes $25 Million Seed Funding to Finalize Preclinical Development and Prepare for First in Humans Trials

·3 min read

IND Application Expected in Early 2022 for Its Lead Product BTM-3566 Company Establishes Operations in the Research Triangle Park

RESEARCH TRIANGLE PARK, N.C., Sept. 16, 2021 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that it has completed a $25 million Seed Funding to finalize its ongoing IND-enabling activities for its lead program, BTM-3566, and consummate preparations for first in human clinical trials. The funding was co-led by Bantam's current investors.

www.bantampharma.com (PRNewsFoto/Bantam Pharmaceutical, LLC)
www.bantampharma.com (PRNewsFoto/Bantam Pharmaceutical, LLC)

Bantam plans to submit its Investigational New Drug application in February 2022 and start Phase 1 clinical studies in patients with B-cell hematological malignancies in the second quarter of 2022. In addition, Bantam has established its operations in the Alexandria cluster based in Research Triangle Park, an area rich in clinical development resources and capabilities.

"This funding enables Bantam Pharmaceutical to be fully prepared to enter the clinic for first in human studies in early 2022, representing a major milestone. We are excited about moving to the next stage of development," said Lionel Goldfrank, Co-founding investor and board member.

BTM-3566 is a novel selective modulator of mitochondrial dynamics, targeting a pathway involved in mitochondrial homeostasis that specifically drives cancer cell apoptosis in a number of tumor types with high unmet need. The company has leveraged a protein translational phenotypic screen to discover its clinical candidate and related compounds.

"This Fall we will raise our Series A round to drive clinical development studies and expand our discovery platform to accelerate our novel drug programs and address the ongoing unmet needs of many different cancers, beginning with B-cell hematological malignancies," said Michael Stocum, President and Chief Executive Officer of Bantam. "Our team remains focused on progressing our fundamental scientific insights along the clinical pathway to transform the treatment of patients with cancer."

About BTM-3566
BTM-3566 is a novel selective modulator of mitochondrial dynamics, targeting a pathway involved in mitochondrial homeostasis that specifically drives cancer cell apoptosis. Bantam has leveraged a protein translational phenotypic drug discovery and precision medicine-based platform approach to identify the pathway and related biomarkers, enabling enrichment of patient populations most likely to respond to BTM-3566. Initial clinical proof of concept will focus on areas of unmet clinical need with initial phase I/II clinical trials planned in relapsed/refractory B-cell hematological malignancies, including Diffuse Large B-cell Lymphoma.

About Bantam Pharmaceutical
Bantam Pharmaceutical is a privately funded biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for difficult-to-treat hematological and solid tumors. The Company's current clinical development strategy is focused on B-cell hematological malignancies with expansion into additional patient cohorts based on responses in biomarker-selected patient populations.

For more information

Media Contact:
Terri Clevenger
Westwicke, an ICR Company
Terri.clevenger@westwicke.com
203-856-4326

Company Contact:
Meghan Reynolds, Chief of Staff
646.598.4823
info@bantampharma.com
www.bantampharma.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/bantam-pharmaceutical-completes-25-million-seed-funding-to-finalize-preclinical-development-and-prepare-for-first-in-humans-trials-301378384.html

SOURCE Bantam Pharmaceutical, LLC